MTOR and glioblastoma: Indeed, although preclinical studies had furnished a strong rationale for developing mTOR-based strategies, a randomized phase II clinical trial showed that Everolimus, a selective inhibitor of mTORC1, was not only ineffective in GBM, but also revealed unexpected toxicity and resulted in a reduced median OS of patients [172].